Lakeway, NY — (US MARKET BUZZ) — 12/19/2014— thenextbigtrade.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market about the small and penny stocks, issues news alert on Cerus Corporation (NASDAQ:CERS), Acorda Therapeutics Inc (NASDAQ:ACOR), Rite Aid Corporation (NYSE:RAD).
Cerus Corporation (NASDAQ:CERS)’s shares gained 5.12% to $6.16. The company on Dec. 18 announced that the U.S. Food and Drug Administration (FDA) has approved the INTERCEPT Blood System for platelets. The INTERCEPT platelet system is approved for ex vivo preparation of pathogen-reduced apheresis platelet components in order to reduce the risk of transfusion-transmitted infection (TTI), including sepsis, and to potentially reduce the risk of transfusion-associated graft versus host disease (TA-GVHD). The approval marks the first time that a system to inactivate pathogens in platelet components will be available in the United States.
Acorda Therapeutics Inc (NASDAQ:ACOR) stock jumped 4.89% to $40.35. The company on Dec. 15 announced that the first patient has been enrolled in a Phase 3 clinical trial of dalfampridine for the treatment of post-stroke walking deficits (PSWD).
This multi-center, double-blind, randomized trial is expected to enroll approximately 540 participants who have experienced an ischemic stroke at least six months prior to enrollment. Participants will receive 10 mg dalfampridine, 7.5 mg dalfampridine, or placebo twice daily for 12 weeks. The primary endpoint of the study is the percentage of patients taking dalfampridine who demonstrate at least a 20% improvement in the 2 Minute Walk Test (2MinWT) compared to those receiving placebo.
Rite Aid Corporation (NYSE:RAD)’s shares jumped 11.88% to $6.78. The company on Dec. 18 reported operating results for its fiscal third quarter ended November 29, 2014. Revenues for the quarter were $6.7 billion versus revenues of $6.4 billion in the prior year’s third quarter. Revenues increased 5.3 percent primarily as a result of an increase in same store sales. Net income was $104.8 million or $0.10 per diluted share compared to last year’s third quarter net income of $71.5 million or $0.04 per diluted share. The improvement in net income resulted primarily from an increase in Adjusted EBITDA and a lower LIFO charge, partially offset by a higher loss on debt retirement related to the redemption of the company’s 10.25% senior secured notes.
thenextbigtrade.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. thenextbigtrade.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed “informational edge” which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at Specialpennystockalert.com.
The assembled information disseminated by thenextbigtrade.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. thenextbigtrade.com does expect that investors will buy and sell securities based on information assembled and presented in thenextbigtrade.com. PLEASE always do your own due diligence, and consult your financial advisor.